Filtered By:
Drug: Eloxatin
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 66 results found since Jan 2013.
The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy
This study was designed to check the combined effect of CD133 siRNA and Oxaliplatin on proliferation, migration, apoptosis, and stemness properties of CRC cells in the HT-29 cell line. MTT assay was performed to define the combined effect of CD133 siRNA and Oxaliplatin on the viability of HT-29 cells, and it showed that the combination of CD133 siRNA and Oxaliplatin could reduce the IC50 of this drug from 32.85 to 19.75 nmol. In order to figure out the effect of this combination therapy on CD133 expression at the gene and protein level, qRT-PCR and western blot were exploited, respectively. The results demonstrated that th...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 16, 2021 Category: Drugs & Pharmacology Authors: Zahra Asadzadeh Behzad Mansoori Ali Mohammadi Tohid Kazemi Ahad Mokhtarzadeh Dariush Shanehbandi Nima Hemmat Afshin Derakhshani Oronzo Brunetti Sahar Safaei Marjan Aghajani Souzan Najafi Nicola Silvestris Behzad Baradaran Source Type: research
Reduction of SIRT1-Mediated Epigenetic Upregulation of Nav1.7 Contributes to Oxaliplatin-Induced Neuropathic Pain
CONCLUSIONS: These findings suggest that reduction of SIRT1-mediated epigenetic upregulation of Nav1.7 in the DRG contributes to the development of oxaliplatin-induced neuropathic pain in rats. The intrathecal drug delivery treatment of activating SIRT1 might be a novel therapeutic option for oxaliplatin-induced neuropathic pain.PMID:37192244
Source: Pain Physician - May 16, 2023 Category: Anesthesiology Authors: Ling-Jun Xu Jing Wang Gui-Dan Li Kai-Feng Shen Xing-Hui He Wei Wu Cui-Cui Liu Source Type: research
POU2F1/DNMT3a Pathway Participates in Neuropathic Pain by Hypermethylation-Mediated LRFN4 Downregulation Following Oxaliplatin Treatment
Neurochem Res. 2023 Aug 18. doi: 10.1007/s11064-023-04011-w. Online ahead of print.ABSTRACTEvidence demonstrates that DNA methylation is associated with the occurrence and development of various neurological diseases. However, the potential target genes undergoing DNA methylation, as well as their involvement in the chemotherapy drug oxaliplatin-induced neuropathic pain, are still unclear. Here, Lrfn4, which showed hypermethylation in the promoter regions, was screened from the SRA methylation database (PRJNA587622) following oxaliplatin treatment. MeDIP and qPCR assays identified that oxaliplatin treatment increased the m...
Source: Neurochemical Research - August 17, 2023 Category: Neuroscience Authors: Yan-Hui Gu Jing Wang Wei-Cheng Lu Yong Cheng Rong Tao Shi-Jia Zhang Ting Xu Ke-Wei Zhai Su-Xia Luo Wen-Jun Xin Source Type: research
Gene Expression Profiling for Analysis Acquired Oxaliplatin Resistant Factors in Human Gastric Carcinoma TSGH-S3 Cells: the Role of IL-6 Signaling and Nrf2/AKR1C Axis Identification.
Abstract
Oxaliplatin treatment is a mainstay of treatment for advanced gastrointestinal tract cancer, but the underlying mechanisms of acquired oxaliplatin resistance remain largely obscured. We previously demonstrated that increased DNA repair capacity and copper-transporting ATPase 1 (ATP7A) level contributed to oxaliplatin resistance in the human gastric carcinoma cell line TSGH-S3 (S3). In the present study, we applied gene array technology to identify additional resistance factors in S3 cells. We found that interleukin-6 (IL-6), aldo-keto reductase 1C1 (AKR1C1), and AKR1C3 are the top 3 upregulated genes in S...
Source: Biochemical Pharmacology - August 8, 2013 Category: Drugs & Pharmacology Authors: Chen CC, Chu CB, Liu KJ, Huang CY, Chang JY, Pan WY, Chen HH, Cheng YH, Lee KD, Chen MF, Kuo CC, Chen LT Tags: Biochem Pharmacol Source Type: research
Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.
CONCLUSION: Girdin knockdown enhances chemosensitivity of colorectal cancer cells to oxaliplatin via TOP2B down-regulation. These findings provide a promising approach to overcome the chemoresistance of colorectal cancer cells.
PMID: 25009397 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - July 7, 2014 Category: Gastroenterology Authors: Zhang YJ, Li AJ, Han Y, Yin L, Lin MB Tags: World J Gastroenterol Source Type: research
Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines.
Authors: Yuan TM, Liang RY, Chueh PJ, Chuang SM
Abstract
The identification of prognostic markers and establishing their value as therapeutic targets improves therapeutic efficacy against human cancers. Ribophorin II (RPN2) has been demonstrated to be a prognostic marker of human cancer, including breast and pancreatic cancers. The present study aimed to evaluate RPN2 expression in gastric cancer and to examine the possible correlation between RPN2 expression and the response of cells to clinical anticancer drugs, which has received little research attention at present. The gastric cancer AGS, TMC-1, SNU-1, TMK-1, ...
Source: Oncology Letters - June 4, 2015 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Down-Regulating Receptor Interacting Protein Kinase 1 (RIP1) Promotes Oxaliplatin-Induced Tca8113 Cell Apoptosis.
CONCLUSIONS Down-regulating RIP1 promotes oxaliplatin induced Tca8113 cells apoptosis.
PMID: 26460489 [PubMed - in process]
Source: Medical Science Monitor - October 16, 2015 Category: Research Tags: Med Sci Monit Source Type: research
ZEB1 Induces Ddr1 Promoter Hypermethylation and Contributes to the Chronic Pain in Spinal Cord in Rats Following Oxaliplatin Treatment
In conclusion, these results suggested that the ZEB1 recruited DNMT3b to the Ddr1 promoter, which induced the DDR1 downregulation and contributed to the oxaliplatin-induced chronic pain.PMID:34032956 | DOI:10.1007/s11064-021-03355-5
Source: Neurochemical Research - May 25, 2021 Category: Neuroscience Authors: Yi-Ying Chen Kai-Sheng Jiang Xiao-Hui Bai Meng Liu Su-Yan Lin Ting Xu Jia-You Wei Dai Li Yuan-Chang Xiong Wen-Jun Xin Zhen-Yu Li Source Type: research
WEE1 Is Regulated by HuR upon DNA Damage
We describe a novel mechanism that PDA cells use to protect against DNA damage in which HuR posttranscriptionally regulates the expression and downstream function of WEE1 upon exposure to DNA-damaging agents. Cancer Res; 74(4); 1128–40. ©2014 AACR.
Source: Cancer Research - February 16, 2014 Category: Cancer & Oncology Authors: Lal, S., Burkhart, R. A., Beeharry, N., Bhattacharjee, V., Londin, E. R., Cozzitorto, J. A., Romeo, C., Jimbo, M., Norris, Z. A., Yeo, C. J., Sawicki, J. A., Winter, J. M., Rigoutsos, I., Yen, T. J., Brody, J. R. Tags: Molecular and Cellular Pathobiology Source Type: research
Oxaliplatin activates the KEAP1/NRF2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
Abstract
Oxaliplatin is an important drug in the treatment of advanced metastatic colorectal cancer. NF-E2 P45-related factor 2 (NRF2) is a key transcription factor that controls genes encoding cytoprotective and detoxifying enzymes through antioxidant response elements (AREs) in their regulatory regions. Here, we report that oxaliplatin is an activator of the NRF2 signaling pathway, with up-regulation of ARE-driven genes and glutathione elevation. An injection of oxaliplatin into mice enhanced the expression of glutathione transferases and antioxidant enzymes in the small and large intestines of wild-type (WT) mi...
Source: Free Radical Biology and Medicine - February 17, 2014 Category: Biology Authors: Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J, Tang X Tags: Free Radic Biol Med Source Type: research
Sensitization of Mesothelioma Cells to Platinum-Based Chemotherapy by GSTπ Knockdown.
Abstract
It is predicted that the incidence of mesothelioma will increase and thus it is important to find new ways to treat this chemoresistant tumor. Glutathione -S-Transferase π (GSTπ) is found at significant levels in mesotheliomas and thus attenuating its intracellular levels may provide a means of sensitizing mesothelioma cells to chemotherapy. GSTπ knockdowns were therefore prepared with shRNA(less off-target effects) employing two cell lines (211H, H2452) that were typed by immunohistochemistry to be of mesothelial origin. The knockdowns exhibited a decrease in both total GST enzyme activity and GSTπ p...
Source: Biochemical and Biophysical Research communications - March 29, 2014 Category: Biochemistry Authors: Chen J, Solomides C, Simpkins H Tags: Biochem Biophys Res Commun Source Type: research
Abstract 2079: EpHA2 is an essential driver of invasion and a novel target in KRAS mutant colorectal cancer
Conclusion
Using our novel comprehensive systems biology approach we have identified novel KRAS synthetic lethal targets and pathways. Combining these findings with targets which are effective against our pre-clinical adjuvant models we have identified EpHA2 as a key driver of invasion and migration and a synthetically lethal target in KRASMT CRC. In addition, we show that EpHA2 is a poor prognostic marker and an important novel target for KRASMT CRC tumors in both the adjuvant and advanced disease setting.
Citation Format: Philip D. Dunne, Darragh G. McArt, Jaine K. Blayney, Sonali Dasgupta, Manuel Salto-Tellez, Patrick G...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Dunne, P. D., McArt, D. G., Blayney, J. K., Dasgupta, S., Salto-Tellez, M., Johnston, P. G., Schaeybroeck, S. V. Tags: Tumor Biology Source Type: research
Abstract 5267: Pro-inflammatory CXCL8 signaling potentiates survival of K-Ras mutant colorectal cancer cells
Conclusions: CXCL8 signaling is elevated in K-Ras and PI3KCA mutant cancers. The up-regulation of autocrine CXCL8 signaling is linked to the promotion of cell survival, principally mediated through the inhibition of apoptosis and promotion of RTK signaling. The clinical relevance of CXCL8 signaling in modulating outcome of K-Ras mutant CRC to current treatments remains to be determined. However, CXCL8-directed therapies may be relevant as chemo-sensitizing agents in K-Ras and/or PIK3CA mutant tumors.
Citation Format: Laura M. Campbell, Olabode Oladipo, Pamela J. Maxwell, Daniel Longley, Richard H. Wilson, David JJ Waugh. P...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Campbell, L. M., Oladipo, O., Maxwell, P. J., Longley, D., Wilson, R. H., Waugh, D. J. Tags: Molecular and Cellular Biology Source Type: research
Identification of anti-metastatic drug and natural compound targets in isogenic colorectal cancer cells.
Abstract
Therapeutic strategies for cancer treatment often remain challenging due to the cumulative risk derived from metastasis, which has been described as an aggressive state of cancer cell proliferation often resulting in failure of clinical therapy. In the current study, anti-metastatic properties of three chemotherapeutic drugs and three compounds from natural sources were investigated by comparative proteomic analysis. Proteomic profile comparison of the isogenic primary and metastatic colon cancer cell lines SW480 and SW620 identified two potential metastasis related molecular targets: fatty acid synthase ...
Source: Journal of Proteomics - October 23, 2014 Category: Biochemistry Authors: Lee JG, McKinney KQ, Pavlopoulos AJ, Park JH, Hwang S Tags: J Proteomics Source Type: research
